|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
4
|
|
pubmed:dateCreated |
2011-2-4
|
|
pubmed:abstractText |
The OCTANE trial reports superior outcomes of lopinavir/ritonavir vs. nevirapine-based antiretroviral therapy (ART) among women previously exposed to single-dose nevirapine to prevent mother-to-child HIV transmission. However, lopinavir/ritonavir is 12 times costlier than nevirapine.
|
|
pubmed:grant |
http://linkedlifedata.com/resource/pubmed/grant/3U01AI32775-13S5,
http://linkedlifedata.com/resource/pubmed/grant/5 U01 AI069518,
http://linkedlifedata.com/resource/pubmed/grant/5U01AI069455-03,
http://linkedlifedata.com/resource/pubmed/grant/5U01AI069456-03,
http://linkedlifedata.com/resource/pubmed/grant/AI-069501,
http://linkedlifedata.com/resource/pubmed/grant/AI69453,
http://linkedlifedata.com/resource/pubmed/grant/K01 AI078754,
http://linkedlifedata.com/resource/pubmed/grant/K01 AI078754-02,
http://linkedlifedata.com/resource/pubmed/grant/K01 AI078754-03,
http://linkedlifedata.com/resource/pubmed/grant/K24 AI062476,
http://linkedlifedata.com/resource/pubmed/grant/K24 AI56933,
http://linkedlifedata.com/resource/pubmed/grant/P30 AI 60354,
http://linkedlifedata.com/resource/pubmed/grant/R01 AI 69453,
http://linkedlifedata.com/resource/pubmed/grant/R01 AI058736,
http://linkedlifedata.com/resource/pubmed/grant/R01 HD044391,
http://linkedlifedata.com/resource/pubmed/grant/T32 AI007433-10,
http://linkedlifedata.com/resource/pubmed/grant/U01 AI068636,
http://linkedlifedata.com/resource/pubmed/grant/U01 AI069424,
http://linkedlifedata.com/resource/pubmed/grant/U01 AI68634,
http://linkedlifedata.com/resource/pubmed/grant/U01 AI69463-03,
http://linkedlifedata.com/resource/pubmed/grant/U01AI069436,
http://linkedlifedata.com/resource/pubmed/grant/U19 AI53217
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Feb
|
|
pubmed:issn |
1473-5571
|
|
pubmed:author |
pubmed-author:CEPAC-International and OCTANE Investigators,
pubmed-author:ChuJenniferJ,
pubmed-author:CiaranelloAndrea LAL,
pubmed-author:ConradieFrancescaF,
pubmed-author:CurrierJudithJ,
pubmed-author:FreedbergKenneth AKA,
pubmed-author:HolmesCharles BCB,
pubmed-author:HughesMichaelM,
pubmed-author:LockmanShahinS,
pubmed-author:LosinaElenaE,
pubmed-author:McIntyreJamesJ,
pubmed-author:PillaySandyS,
pubmed-author:WalenskyRochelle PRP,
pubmed-author:WoodRobinR
|
|
pubmed:issnType |
Electronic
|
|
pubmed:day |
20
|
|
pubmed:volume |
25
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
479-92
|
|
pubmed:dateRevised |
2011-11-17
|
|
pubmed:meshHeading |
pubmed-meshheading:21293199-Adult,
pubmed-meshheading:21293199-Anti-HIV Agents,
pubmed-meshheading:21293199-Cost-Benefit Analysis,
pubmed-meshheading:21293199-Female,
pubmed-meshheading:21293199-HIV Infections,
pubmed-meshheading:21293199-Humans,
pubmed-meshheading:21293199-Infant, Newborn,
pubmed-meshheading:21293199-Infectious Disease Transmission, Vertical,
pubmed-meshheading:21293199-Life Expectancy,
pubmed-meshheading:21293199-Lopinavir,
pubmed-meshheading:21293199-Male,
pubmed-meshheading:21293199-Nevirapine,
pubmed-meshheading:21293199-Pregnancy,
pubmed-meshheading:21293199-Pyrimidinones,
pubmed-meshheading:21293199-Ritonavir,
pubmed-meshheading:21293199-South Africa,
pubmed-meshheading:21293199-Treatment Outcome
|
|
pubmed:year |
2011
|
|
pubmed:articleTitle |
First-line antiretroviral therapy after single-dose nevirapine exposure in South Africa: a cost-effectiveness analysis of the OCTANE trial.
|
|
pubmed:affiliation |
Division of Infectious Disease, Massachusetts General Hospital, Boston, 02114, USA. aciaranello@partners.org
|
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't,
Research Support, N.I.H., Extramural
|
